[4] Due to the high demand for GLP-1 drugs in the U.S
Numerous studies show that BV boosts Fos transcription and decreases nociceptive behavior
References McIntyre CA, Lawrence SA, Richards AL, Chou JF, Wong W, Capanu M, et al
Since GLP-1 receptor agonists are effective in addressing both weight management and insulin resistance - two significant factors in PCOS - they have become a valuable option for symptom management, even without FDA approval for this specific condition
Conclusion Overall, when it comes to prescribing GLP1-RAs for weight loss to patients with a history of cholelithiasis or other gallbladder disorders, providers should use caution
This is a known adverse drug reaction but is not a contraindication or true allergy